Indian pharmaceutical sector is estimated to grow to US$ 130 billion by 2030. Branded generics dominate the pharmaceuticals market, constituting nearly 80% of the market share in terms of revenues.

Pharma sector is expected to generate 58,000 additional job opportunities by 2025. Indian companies received 375 Abbreviated New Drug Application (ANDA) approvals from the USFDA accounting for 50% of total final ANDA approvals in 2023. A large pipe-line of high-value drugs as well as decline in regulatory alerts for larger companies is expected to drive growth.

This smallcase comprises pharmaceutical and life sciences companies to allow investors to efficiently track and invest in the pharma sector.